Table 1.
Patient characteristics according to diabetes mellitus (DM) status.
| Variable | All (n = 221) | Non-DM (n = 144) | DM (n = 77) | p |
|---|---|---|---|---|
| Age (year) | 60 (50, 67) | 57 (49, 66) | 62 (52, 68) | 0.031 |
| Gender (Male, %) | 131 | 76 (52.8) | 55 (59.3) | 0.007 |
| Body mass index (kg/m2) | 23.63 (21.15, 26.04) | 23.11 (21.15, 25.51) | 26.34 (21.78, 26.25) | 0.071 |
| Fasting glucose (mmol/L) | 5.51 (4.91, 6.85) | 5.18 (4.77, 5.65) | 7.57 (5.87, 9.55) | <0.0001 |
| 2 h OGTT (mmol/L) | 8.70 (6.98, 12.41) | 7.40 (6.53, 8.55) | 13.70 (12.30, 17.44) | <0.0001 |
| HbA1c (%) | 6.1 (5.6, 6.7) | 5.9 (5.6, 6.2) | 6.8 (6.2, 8.6) | <0.0001 |
| Fasting insulin (umol/L) a | 6.21 (3.62, 9.96) | 5.83 (3.60, 9.47) | 7.50 (3.58, 12.08) | 0.157 |
| Fasting C-peptide (pmol/L) b | 0.49 (0.38, 0.71) | 0.47 (0.38, 0.67) | 0.53 (0.39, 0.77) | 0.250 |
| HOMA2-B a | 87.30 ± 41.94 | 95.89 ± 36.17 | 68.91 ± 47.53 | <0.0001 |
| HOMA2-IR a | 1.21 (0.88, 1.82) | 1.12 (0.84, 1.61) | 1.43 (1.03, 2.10) | 0.003 |
| Tumor volume (cm3) | 4.00 (1.52, 10.40) | 2.55 (1.00, 8.75) | 7.92 (2.88, 13.68) | <0.0001 |
| Location, (body and tail %) | 101 (45.7) | 65 (45.1) | 36 (46.8) | 0.818 |
| AJCC stage (Ⅲ~Ⅳ, %) | 39 (18) | 18 (12.5) | 21 (34.8) | 0.006 |
| CA19-9 | 18.00 (9.41, 55.00) | 17.50 (9.80, 44.96) | 19.00 (7.52, 77.00) | 0.699 |
| Total bilirubin (umol/L) | 11.10 (8.40, 13.40) | 10.80 (8.20, 13.08) | 11.50 (8.80, 14.30) | 0.211 |
| Alanine aminotransferase (IU/L) | 18.00 (12.00, 28.00) | 18.00 (13.00, 25.00) | 18.00 (11.50, 32.00) | 0.371 |
| Albumin (g/L) | 43.20 (40.65, 46.10) | 43.10 (40.9, 45.88) | 43.40 (39.60, 46.25) | 0.838 |
| Creatinine (umol/L) | 66.00 (56.00, 77.00) | 63.00 (54.25, 76.75) | 67.00 (58.50, 77.50) | 0.073 |
| Triglyceride (mmol/L) | 1.16 (0.87, 1.49) | 1.10 (0.85, 1.48) | 1.21 (0.94, 1.54) | 0.144 |
| Cholesterol (mmol/L) | 4.26 ± 0.95 | 4.31 ± 0.96 | 4.18 ± 0.93 | 0.322 |
| High density lipoprotein (mmol/L) | 1.20 (0.99, 1.52) | 1.22 (1.03, 1.52) | 1.15 (0.94, 1.46) | 0.089 |
| Low density lipoprotein (mmol/L) | 2.48 (2.01, 2.95) | 2.49 (1.99, 2.98) | 2.48 (2.21, 2.94) | 0.913 |
| Hemoglobin (g/L) | 132.29 ± 14.61 | 131.28 ± 14.59 | 134.17 ± 14.56 | 0.161 |
| White blood cell(109/L) | 5.37 (4.58, 6.34) | 5.12 (4.32, 5.99) | 5.84 (4.96, 7.52) | <0.0001 |
| Platelet (109/L) | 145.00 (120.75, 182.25) | 132.50 (114.25, 168.00) | 170.00 (141.00, 200.00) | <0.0001 |
| Neutrophil (109/L) | 3.31 (2.73, 4.26) | 2.10 (2.40, 3.90) | 3.82 (2.91, 4.80) | <0.0001 |
| Lymphocyte (109/L) | 1.46 (1.14, 1.76) | 1.46 (1.15, 1.73) | 1.48 (1.10, 1.89) | 0.967 |
| Monocyte (109/L) | 0.39 (0.31, 0.51) | 0.37 (0.29, 0.45) | 0.46 (0.34, 0.59) | <0.0001 |
| NLR | 2.41 (1.85, 3.02) | 2.31 (1.81, 2.79) | 2.55 (1.91, 3.59) | 0.003 |
| PLR | 107.69 (83.06, 134.06) | 103.62 ± 33.71 | 131.18 ± 62.49 | <0.0001 |
| SII (1011/L) | 3.42 (2.96, 4.58) | 3.19 (2.50, 3.71) | 4.41 (3.43, 6.23) | <0.0001 |
a, a fasting insulin test was performed for 179 patients, and the value of HOMA-B and HOMA-IR were calculated. b, a fasting C-peptide test was performed in 140 patients. HbA1c, glycated hemoglobin, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SII, systemic immune-inflammation index. The significance level was set as p < 0.05 (compared to the non-DM group).